S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
NASDAQ:LPTX

Leap Therapeutics (LPTX) Stock Price, News & Analysis

$2.97
-0.02 (-0.67%)
(As of 02/23/2024 ET)
Today's Range
$2.89
$3.04
50-Day Range
$2.44
$4.78
52-Week Range
$1.24
$10.20
Volume
76,222 shs
Average Volume
265,349 shs
Market Capitalization
$75.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.13

Leap Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
375.6% Upside
$14.13 Price Target
Short Interest
Healthy
2.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.10) to ($2.24) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.33 out of 5 stars

Medical Sector

538th out of 939 stocks

Pharmaceutical Preparations Industry

251st out of 438 stocks


LPTX stock logo

About Leap Therapeutics Stock (NASDAQ:LPTX)

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase I clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

LPTX Stock Price History

LPTX Stock News Headlines

LPTX Mar 2024 7.000 call
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024.
The same catalyst the kicked off the three major crypto bull markets... is about to hit again on April 22, 2024
LPTX Jun 2024 1.000 call
LPTX Mar 2024 1.000 call
One company did the impossible with AI
It is the first company in the world to bring an AI-designed drug to clinical trials. It is now working with some of the biggest companies in the world to develop other treatments and is less than $10 today… but Wall Street has been moving in quickly buying up millions of shares.
Recap: Leap Therapeutics Q3 Earnings
Leap Therapeutics (LPTX) Receives a Buy from H.C. Wainwright
Leap Therapeutics (LPTX) Receives a Buy from Raymond James
See More Headlines
Receive LPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
2/23/2024
Next Earnings (Estimated)
3/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LPTX
Fax
N/A
Employees
44
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.13
High Stock Price Target
$20.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+375.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-54,600,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.50 million
Book Value
$5.94 per share

Miscellaneous

Free Float
22,676,000
Market Cap
$75.94 million
Optionable
Optionable
Beta
0.59
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Douglas E. Onsi J.D. (Age 55)
    CFO, General Counsel, Treasurer & Secretary, President, CEO & Director
    Comp: $1.04M
  • Mr. Augustine J. Lawlor (Age 67)
    Chief Operating Officer
    Comp: $713.57k
  • Dr. Cynthia A. Sirard (Age 54)
    Chief Medical Officer
    Comp: $708.64k
  • Dr. Jason S. Baum Ph.D. (Age 45)
    Chief Scientific Officer
  • Mr. Mark O'Mahony (Age 53)
    Chief Manufacturing Officer
  • Ms. Christine M. Granfield (Age 56)
    VP and Head of Regulatory Affairs & Quality














LPTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Leap Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LPTX shares.
View LPTX analyst ratings
or view top-rated stocks.

What is Leap Therapeutics' stock price target for 2024?

4 Wall Street analysts have issued 1-year price objectives for Leap Therapeutics' stock. Their LPTX share price targets range from $7.00 to $20.00. On average, they anticipate the company's share price to reach $14.13 in the next year. This suggests a possible upside of 375.6% from the stock's current price.
View analysts price targets for LPTX
or view top-rated stocks among Wall Street analysts.

How have LPTX shares performed in 2024?

Leap Therapeutics' stock was trading at $4.15 at the beginning of 2024. Since then, LPTX stock has decreased by 28.4% and is now trading at $2.97.
View the best growth stocks for 2024 here
.

When is Leap Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 22nd 2024.
View our LPTX earnings forecast
.

How were Leap Therapeutics' earnings last quarter?

Leap Therapeutics, Inc. (NASDAQ:LPTX) posted its quarterly earnings data on Monday, November, 13th. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.07.

When did Leap Therapeutics' stock split?

Leap Therapeutics shares reverse split on Wednesday, June 21st 2023. The 1-10 reverse split was announced on Wednesday, June 21st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Leap Therapeutics own?
Who are Leap Therapeutics' major shareholders?

Leap Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (1.60%), Key Client Fiduciary Advisors LLC (0.84%), Price T Rowe Associates Inc. MD (0.47%), Price T Rowe Associates Inc. MD (0.47%), Northern Trust Corp (0.17%) and Simplex Trading LLC (0.00%).
View institutional ownership trends
.

How do I buy shares of Leap Therapeutics?

Shares of LPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LPTX) was last updated on 2/23/2024 by MarketBeat.com Staff